IRVINE, Calif., Dec. 16, 2021 /PRNewswire/ — Predictive Health Diagnostics Company, Inc. (“PHDC” or “the Company”), a diagnostics platform company that develops, manufactures, and distributes specialty diagnostic tests that detect diseases with significant unmet medical needs and facilitate improved patient care, today announced that the Pennsylvania Department of Health has issued a clinical laboratory permit (CLP) to Morningstar Laboratories (“Morningstar”).
Predictive Health Diagnostics Company (PRNewsfoto/Predictive Health Diagnostics Company)
Douglas S. Harrington, M.D., PHDC Chief Medical Officer and Morningstar Laboratories Director commented, “Morningstar’s CLP for the state of Pennsylvania is highly significant to PHDC’s growth and expansion of services into targeted regions. As the fifth most populous state in the U.S., Pennsylvania has a vast healthcare landscape, but one challenged with unmet medical needs and broad disparities in access to healthcare services. Morningstar’s entry into Pennsylvania enables us to provide much needed laboratory services to large communities, both urban and rural, while also adding another state to our certification footprint, now spanning 4 states, including the 1st and 5th most populous.
“Due to the pandemic and even at the present time, Pennsylvania’s healthcare system is overburdened with daily COVID-19 cases that are amongst the highest in our country,” Dr. Harrington added. “Morningstar’s COVID-19 antibody testing services provide another much-needed resource for hospitals, physicians and patients statewide.”
Morningstar, a PHDC company, is a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory and is accredited by the College of American Pathologists (CAP). In addition to Pennsylvania, Morningstar holds current licensures for its operations in California, Rhode Island, and Maryland.
About Predictive Health Diagnostics Company
Predictive Health Diagnostics Company (PHDC) is a leading specialty diagnostics development platform company that develops, manufactures, and distributes unique medical tests combining science, technology, and proprietary analytics that detect diseases with significant unmet medical needs and support better therapeutic outcomes. The Company’s PULS Cardiac Test™, marketed in the U.S., the Middle East, Asia, and Canada, identifies asymptomatic patients at risk of a heart attack who are missed by the current standard of care, and its DIABETESpredict™ test, distributed throughout North America, identifies genetic risk of type 2 diabetes before symptoms or abnormal lab results are discovered, and provides in depth information to those already diagnosed. PHDC’s laboratory information systems use data from multiple sources including proteomics, genetics, metabolics, biochemistry, phenotype, and imaging to address among the most challenging clinical problems. Morningstar Laboratories, a PHDC company, is a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited laboratory offering comprehensive and customized services based on Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit PHDC at phdiagnostics.com, Twitter, Facebook, and LinkedIn.
Forward-looking statements are based on our current expectations and assumptions regarding our business, our industry, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. We caution you therefore against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance.
Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.